This was the stock's second consecutive day of losses.

San Francisco observed World AIDS Day with a public program at the National AIDS Memorial Grove in Golden Gate Park.

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

Catch up on all the biggest pharma news to hit the industry last month, with stories spanning the US election, new ...

GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.

Timely remdesivir treatment in immunocompromised patients infected with COVID-19 is associated with improved survival outcomes.

Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a ...

University of Colorado professor Leslie Leinwand thinks studying python hearts could lead to treatments for human heart disease ...

The stock's fall snapped an eight-day winning streak.